Sign in Subscribe
Vaccines

Travel Vaccines Market to Reach $12.1 Billion by 2034

Strategic Insights

— 1 min read

The global travel vaccines market is rapidly growing due to a combination of factors, including increasing awareness of global health risks, advances in vaccine development, and evolving international travel patterns. The market, which was valued at $4.9 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 9.9 percent to reach $12.1 billion by 2034. This growth is driven by the increasing recognition of regional disease risks and the critical role of vaccination in preventing illness while abroad.

Key Takeaways:

  • The global travel vaccines market was valued at $4.9 billion in 2024 and is expected to grow to $12.1 billion by 2034 at a CAGR of 9.9 percent.
  • The market is driven by increasing awareness of global health risks, advances in vaccine development, and evolving international travel patterns.
  • The mono vaccines segment generated $2.9 billion in 2024 and is forecast to reach $7.1 billion by 2034 at a CAGR of 9.7 percent.
  • The Hepatitis A vaccine held a 20.2 percent share in 2024 due to its essential role in protecting against food and water-borne illness in regions with poor sanitation.
  • The United States Travel Vaccines Market generated $1.9 billion in 2024 and is expected to grow at a CAGR of 9.3 percent between 2025 and 2034.
  • The market is segmented into mono and combination vaccines, distributed through both public and private healthcare channels.
  • Leading players in the global travel vaccines market include Meiji Group, Dynavax Technologies, Serum Institute of India, Sanofi, GlaxoSmithKline plc (GSK), Valneva SE, Bharat Biotech, Pfizer, CSL, Emergent BioSolutions, Merck, and Bavarian Nordic.

Statistics:

  • Market value in 2024: $4.9 billion
  • Forecasted market value by 2034: $12.1 billion
  • CAGR: 9.9 percent
  • Mono vaccines segment value in 2024: $2.9 billion
  • Forecasted mono vaccines segment value by 2034: $7.1 billion
  • CAGR of mono vaccines segment: 9.7 percent
  • Hepatitis A vaccine share in 2024: 20.2 percent
  • United States Travel Vaccines Market value in 2024: $1.9 billion
  • Forecasted United States Travel Vaccines Market value by 2034: $4.5 billion
  • CAGR of United States Travel Vaccines Market: 9.3 percent

Sources:

  • "Travel Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" - ResearchAndMarkets.com
  • Report information: https://www.researchandmarkets.com/r/pemjvd

Read more